Agios Pharmaceuticals Inc (STU:8AP)
€ 56 0 (0%) Market Cap: 3.20 Bil Enterprise Value: 2.30 Bil PE Ratio: 5.18 PB Ratio: 2.06 GF Score: 28/100

Agios Pharmaceuticals Inc ENERGIZE Phase 3 Topline Results Transcript

Jan 03, 2024 / 01:00PM GMT
Release Date Price: €21.6 (+3.85%)
Operator

Good morning and welcome to our GEO's webcast and conference call regarding the energize Phase three study. (Operator Instructions) Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Chris Taylor, VP, Investor Relations and Corporate Communications for Agios. Please go ahead.

Christopher Taylor
Agios Pharmaceuticals Inc - Vice President, Investor Relations and Corporate Communications

Thank you, operator. Good morning, everyone, and welcome to Agios' webcast and conference call highlighting the top-line data of the energize Phase three study You can access slides for today's call by going to the Investors section of our website, agios.com. On today's call, you will hear from our Chief Executive Officer, Brian Goff, Dr. Sarah humans, Chief Medical Officer and Head of Research and Development, Dr. Jeremy E step Medical Director for Agios and thalassemia, and joining for Q&A. Cecilia Jones, Chief Financial Officer, and set a mill Inova, our Chief Commercial Officer.

Before we get

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot